

2ND MULTI-STAKEHOLDER

Symposium

22-23
FEBRUARY 2017
HOTEL LE PLAZA
BRUSSELS

ON IMPROVING
PATIENT ACCESS
TO RARE DISEASE
THERAPIES



A cooperative process to reach mutually acceptable solutions that respects all stakeholders, improves our common understanding and establishes sustainable mutual trust

PRELIMINARY PROGRAMME

DAY 1: Wednesday, 22 February 2017

09.00 to 18.30

09.00 – 13.00	<p>INTRODUCTION & OPENING PLENARY EXPRESSION OF STAKEHOLDER INTERESTS</p> <p><i>Live video streaming</i> <i>Co-Chairs: Peter O'Donnell, Politico, Belgium (tbc) & Charles Barker, PrimeMover Associates, USA (confirmed)</i></p>
09.00 - 09.15	Welcome & Introduction Charles Barker, PrimeMover Associates, USA (confirmed)
09.15 – 09.30	Setting the scene Yann Le Cam, Chief Executive Officer, EURORDIS (confirmed)
09.30 – 09.40	Patient case study Speaker to be named
09.40 – 09.55	The role of the European Commission on improving access to rare disease therapies Speaker to be named
09.55 – 11.25	<p>PANEL discussion: moderated by Co-Chairs Industry decision-makers</p> <p>What have been the most important changes in the last year? What are the challenges? What are the options moving forward? How do we work together to improve this? Panellists and questioners to be named Q&A from on-site and online audiences</p>
11.25 – 11.40	<i>Coffee break</i>
11.40 – 13.00	<p>PANEL discussion: moderated by Co-Chairs Policy decision-makers</p> <p>What have been the most important changes in the last year? What are the challenges? What are the options moving forward? How do we work together to improve this? Panellists and questioners to be named Q&A from on-site and online audiences</p>
13.00 – 14.00	<i>LUNCH (Salon Adolphe Max)</i>
14.00 – 18.30	PLENARY
14.00 – 14.10	Patient case study Speaker to be named
14.10 – 14.55	Current state of the art in multi-stakeholder collaborative processes

	Early dialogue initiatives & expedited regulatory pathways Speakers to be named
14.55 – 15.10	Collaborating for success Karen Facey, HTAi, UK (confirmed)
15.10 – 16.15	Multi-stakeholder panel discussion: success factors for collaboration in relation to access Panellists to be named Q&A from on-site and online audiences
16.15 – 16.30	<i>Coffee break</i>
16.30 – 18.00	From diverging positions to common interests A collaborative conversation for transformative operational solutions serving the interests of each stakeholder Moderator: Charles Barker, PrimeMover Associates, USA (confirmed)
18.00 – 18.30	Conclusions from Day 1 Co-Chairs
18.30	End of Day 1

DAY 2: Thursday, 23 February 2017

08.00 – 18.00

08.00 – 09.00	PLENARY <i>Co-Chair: Sheela Upadhyaya, NICE, UK (tbc)</i> <i>Co-chair: to be named</i>		
08.00 – 08.15	Trajectory from Day 1 & Aims of Day 2 Session Chairs		
08.15 – 08.25	Patient case study Speaker to be named		
08.25 – 08.45	Introduction to breakout sessions Moderators of breakouts		
09.00 – 11.00	BREAKOUT SESSIONS – Emerging options		
	Breakout 1: Quality Data Generation	Breakout 2: Value for money across Europe	Breakout 3: Pricing

	Pan-European disease & product registries to address needs of all stakeholders Moderator & Rapporteur to be named	Common principles for value determination and assessment Moderator: Lieven Annemans, Ghent University, Belgium (tbc) Rapporteur: to be named	Innovative performance based outcome agreements Moderator & Rapporteur to be named
11.00 – 11.15	<i>Coffee break</i>		
11.15 – 12.30	PLENARY <i>Co-Chair: Sheela Upadhyaya, NICE, UK (tbc)</i> <i>Co-chair: to be named</i>		
11.15 – 12.30	Feedback and discussion from breakout sessions Co-Chairs & rapporteurs from breakouts		
12.30 – 13.30	<i>LUNCH (Salon Adolphe Max)</i>		
13.30 – 15.30	BREAKOUT SESSIONS - New options		
	Breakout 1: Quality Data Generation	Breakout 2: Value for money across Europe	Breakout 3: Pricing
	How European Reference Networks (ERNs) could become part of the solution / enablers of quality data generation? Moderator & Rapporteur to be named	Proposals for coordination of HTA across Europe: implications for rare diseases Moderator & Rapporteur to be named	Potential for European collaboration among payers and companies Moderator & Rapporteur to be named
15.30 – 15.45	<i>Coffee break</i>		
15.45 – 18.00	PLENARY <i>Co-Chairs to be named</i>		
15.45 – 16.45	Feedback and discussion from breakout sessions Co-Chairs & rapporteurs from breakouts		
16.45 – 17.45	Panel discussion: Paving the way to a fair, inclusive and on-going multi-stakeholder approach with the potential to generate sustainable, affordable and actionable improvements in patient access to rare disease therapies Panellists to be named Q&A		
17.45 – 18.00	Conclusions & closing remarks Yann Le Cam, Chief Executive Officer, EURORDIS (tbc)		
18.00	End of Day 2 – End of symposium		